A Phase 1, First-in-Human, 2-Part, Multicenter Dose Escalation and Repeat Dose Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs TAK 101 (Primary)
- Indications Coeliac disease
- Focus Adverse reactions; First in man
- Sponsors Cour Pharmaceutical Development
- 18 Jun 2019 Status changed from active, no longer recruiting to completed.
- 29 Jan 2019 Planned End Date changed from 1 Mar 2019 to 29 May 2019.
- 29 Jan 2019 Planned primary completion date changed from 1 Nov 2018 to 29 May 2019.